ReviewThe journal of prevention of Alzheimer's disease2018
Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach.
Review in The journal of prevention of Alzheimer's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer's disease: A systematic review.Frontiers in aging neuroscience · 2022Pooled it
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Role of apolipoprotein E4 in alzheimer's disease pathogenesis and emerging therapeutic strategies.Metabolic brain disease · 2025Review
- Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Medical risk factors, ApoE haplotype, and Alzheimer's disease: a large-scale analysis.The journal of prevention of Alzheimer's disease · 2025Article
- Differences in Alzheimer's Disease-Related Pathology Profiles Across Apolipoprotein Groups.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- A lifetime perspective on risk factors for cognitive decline with a special focus on early events.Cerebral circulation - cognition and behavior · 2024Article
- Alzheimer's disease: an epidemiological analysis over the number of hospitalizations and deaths in Brazil.Arquivos de neuro-psiquiatria · 2023Observational
- Research gaps and opportunities in precision nutrition: an NIH workshop report.The American journal of clinical nutrition · 2022Article
- Predicting conversion to Alzheimer's disease in individuals with Mild Cognitive Impairment using clinically transferable features.Scientific reports · 2022Article
- Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.Dementia & neuropsychologia · 2022Article
- Effects of sex and genotype in human APOE-targeted replacement mice on alcohol self-administration measured with the automated IntelliCage system before and after repeated mild traumatic brain injury.Alcoholism, clinical and experimental research · 2021Article
- Assessment of Screening Approach in Early and Differential Alzheimer's Disease Diagnosis.Antioxidants (Basel, Switzerland) · 2021Article
- Biomarker-guided drug therapy: personalized medicine for treating Alzheimer's disease.Neural regeneration research · 2021Article
- Article
- A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE ε4 Carriers.The journal of nutrition, health & aging · 2021Article
- Traumatic Brain Injury Exposure Lowers Age of Cognitive Decline in AD and Non-AD Conditions.Frontiers in neurology · 2021Article
- Genetic Risk Factors for Alzheimer's Disease in Racial/Ethnic Minority Populations in the U.S.: A Scoping Review.Frontiers in public health · 2021Article
- Alzheimer's Disease and Oral-Systemic Health: Bidirectional Care Integration Improving Outcomes.Frontiers in oral health · 2021Article
- Genetic architecture of common non-Alzheimer's disease dementias.Neurobiology of disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Population-attributable risk models estimate that up to one-third of Alzheimer's disease (AD) cases may be preventable through risk factor modification. The field of AD prevention has largely focused on addressing these factors through universal risk reduction strategies for the general population. However, targeting these strategies in a clinical precision medicine fashion, including the use of genetic risk factors, allows for potentially greater impact on AD risk reduction. Apolipoprotein E (APOE), and specifically the APOE ε4 variant, is one of the most well-established genetic influencers on late-onset AD risk. In this review, we evaluate the impact of APOE ε4 carrier status on AD prevention interventions, including lifestyle, nutrigenomic, pharmacogenomic, AD comorbidities, and other biological and behavioral considerations. Using a clinical precision medicine strategy that incorporates APOE ε4 carrier status may provide a highly targeted and distinct approach to AD prevention with greater potential for success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.